Methods for the treatment and prevention of ocular disorders

Inventors

Houck, David Renwick

Assignees

Scynexis Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-8551952-B2

Patent

Publication Date

2013-10-08

Expiration Date


Abstract

Provided herein are methods for treatment of ocular diseases. The methods comprise administering a compound of general Formula (I): wherein R1, R2, R3, R4 and Ak are as defined in the specification.

Core Innovation

The partial content describes 3-substituted cyclosporin Formula (I) derivatives, including 3-[2-(morpholin-4-yl)ethoxy]cyclosporin, for treating or preventing dry eye, uveitis, and phacoanaphylactic endophthalmitis. The claims cover Formula (I) compounds and pharmaceutically acceptable salts, as well as treatment of dry eye with the named morpholine-substituted cyclosporin, alone or with a second agent effective for dry eye.

The specification identifies improved aqueous solubility over cyclosporin A as a formulation advantage and reports inhibition of human T-cell cytokine production and murine mixed lymphocyte response, together with ocular tolerability findings. The partial content does not include the background section and therefore does not explicitly describe the problem being solved. It also describes ophthalmic formulations and combination therapy with a second ocular-disease treatment agent.

Claims Coverage

The relevant claims include three independent claims: claim 1 covers treatment of specified ocular diseases using Formula (I) compounds; claim 6 covers treatment of dry eye using a named cyclosporin derivative; and claim 7 covers that dry-eye treatment in combination with a second agent.

Treatment of specified ocular diseases with Formula (I) compounds

Claim 1 covers treating dry eye, uveitis, or phacoanaphylactic endophthalmitis with a therapeutically effective amount of a Formula (I) compound or pharmaceutically acceptable salt. The claim specifies an alkylene linker; a nitrogen-containing heterocyclic group for R1; isobutyl for R2; (E)-2-butenyl-1 or n-butyl for R3; and ethyl, 1-hydroxyethyl, isopropyl, or n-propyl for R4. Dependent claims further specify ring options, N-morpholine, and linker features.

Treatment of dry eye with 3-[2-(morpholin-4-yl)ethoxy]cyclosporin

Claim 6 covers treating dry eye with a therapeutically effective amount of 3-[2-(morpholin-4-yl)ethoxy]cyclosporin or a pharmaceutically acceptable salt thereof.

Combination treatment of dry eye

Claim 7 covers treating dry eye with 3-[2-(morpholin-4-yl)ethoxy]cyclosporin or a pharmaceutically acceptable salt thereof, together with a second agent effective for the treatment of dry eye.

The independent claims cover Formula (I)-based treatment of three specified ocular diseases, treatment of dry eye with the named cyclosporin derivative, and combination treatment of dry eye with a second effective agent.

Stated Advantages

The specification identifies improved aqueous solubility over cyclosporin A as a formulation advantage.

Documented Applications

Treatment or prevention of dry eye, uveitis, and phacoanaphylactic endophthalmitis using 3-substituted cyclosporin Formula (I) derivatives.

Treatment of dry eye using 3-[2-(morpholin-4-yl)ethoxy]cyclosporin, alone or with a second agent effective for dry eye.

Ophthalmic formulations of the described cyclosporin derivatives.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.